Revance and Teoxane Announce the FDA Approval of RHA® Dynamic Volume for Midface Contour Deficiencies

Nashville, Tenn., January 13, 2026

Revance and Teoxane announce the FDA approval of RHA® Dynamic Volume from the Teoxane RHA® Collection for cheek augmentation and/or the correction of age-related midface contour deficiencies, in adults aged 22 years or older. Formerly known as RHA® 4 Mepi, the product will formally launch under its new name, RHA® Dynamic Volume, in Q1 2026.

Designed to provide dynamic contour enhancement and structural support, RHA® Dynamic Volume delivers lasting volume with its high dynamic strength and stretch, and the ability to maintain its structural integrity. RHA® Dynamic Volume is powered by Preserved Network Technology (PNT), a gentle, heatless, homogenous crosslinking process that helps preserve the natural structure of hyaluronic acid.

“We are incredibly proud of the approval for midface with RHA® Dynamic Volume. This news marks the second major advancement from the Teoxane RHA® Collection in the past few months, following the evolution of the collection through the introduction of the local anesthetic Mepivacaine in late August. The new midface indication enables us to meet more patient needs than ever before,” shares Nadeem Moiz, CEO of Revance. “Revance remains committed to innovating and providing diverse treatment options to address a variety of patient concerns.”

This approval is supported by positive results from the 52-week Phase III clinical trial program, where the efficacy and safety of RHA® Dynamic Volume were evaluated in a prospective, randomized, between-subjects, double-blinded, multicenter head-to-head study with Juvéderm® Voluma® XC, in patients with moderate to severe midface volume deficiency.

Results demonstrated that RHA® Dynamic Volume showed comparable effectiveness to Voluma®, with patients treated with RHA® Dynamic Volume requiring fewer treatment sessions and touch-ups to achieve similar outcomes. Patients reported improved satisfaction with cheek attractiveness, youthfulness, smoothness, contour, and symmetry, and more than 94% of participants reported natural-looking and feeling results at rest and in motion up to one year post-treatment. Patients also reported no perception of restricted facial movement, further confirming the filler’s adaptability to dynamic facial expressions.

During the clinical trial program, 75% of subjects were treated in both superficial fat and deep fat to achieve balanced volume restoration, utilizing a contemporary treatment approach aimed at optimizing outcomes through comprehensive midface volume correction with efficient product use. RHA® Dynamic Volume demonstrated a favorable safety profile, with no late-onset or serious treatment-related adverse events, and no events deemed to be granulomas or delayed inflammatory responses.

“This study marks the U.S. introduction of a midface contouring approach that has been supported by more than a decade of post-marketing surveillance in Europe,” states Sandra Chennoufi, Chief Scientific Officer of Teoxane. “By leveraging the versatility of RHA® Dynamic Volume and the Teoxane MLT Multilayering Technique™, physicians can now address midface volume deficiencies by targeting multiple tissue depths for both deep and superficial fat pads.”

The Teoxane MLT Multilayering Technique™ is a tailored injection approach designed for midface volume restoration using a single adaptable gel—RHA® Dynamic Volume. This technique involves strategically placing the product into the subcutaneous and supraperiosteal layers to restore volume, redefine contours, and harmonize facial proportions according to each patient’s anatomy and aging pattern.

RHA® Dynamic Volume provides deep structural support while allowing for natural tissue integration and facial expressiveness due to its unique rheological profile, combining high projection capacity with dynamic adaptability. Rooted in anatomical precision and Teoxane’s ATP approach (Anatomy, Assessment & Ageing, Technique, Product), the Teoxane MLT Multilayering Technique™ emphasizes safety and precision by identifying and avoiding high-risk vascular zones. The result is a subtle, natural rejuvenation that enhances facial harmony without overcorrection.

Double board-certified facial plastic surgeon and Clinical Assistant Professor at the University of Illinois, Dr. Steven Dayan, states: “The approval of RHA® Dynamic Volume for midface is an exciting advancement for the entire industry. The results we discovered during the study were incredibly profound, and I’m excited to be able to offer a tailored treatment option for my patients.”

About Revance

Revance is a fast-growing, global aesthetics and skincare company committed to delivering innovative aesthetics and market-leading skincare solutions across every stage of life. With a differentiated portfolio and strong market position, Revance meets the evolving needs of patients and consumers worldwide through continued innovation and commercialization of new products and treatments.

Revance’s portfolio includes DAXXIFY® (daxibotulinumtoxinA-lanm) for injection, the Teoxane RHA® Collection, and SkinPen®, an industry-leading microneedling device. RHA® technology is proprietary to and manufactured in Switzerland by Teoxane SA, and Revance is the independent U.S. distributor of the Teoxane RHA® Collection. Revance’s consumer skincare portfolio includes brands such as PanOxyl®, Blue Lizard®, StriVectin® and BIOJUVE®.

Learn more at Revance.com and RevanceAesthetics.com.

References

1. Data on File. TEO-®-2004. Geneva, Switzerland, Teoxane S.A., 2025
2. Faivre et al. Dermatologic Surgery. 2021;47(5):159–167
3. Vantou et al. Published Industry Abstract, ASDS 2024
4. RHA® Dynamic Volume Directions for Use. 2025
5. Flégeau et al. Plastic and Reconstructive Surgery Global Open. 2025;13(2):e6560
6. Galadari et al. Journal of Cosmetic Dermatology. 2022;21(3):924–932
7. Trévidic et al. Aesthetic Surgery Journal. 2022;42(8):920–934
8. Trévidic et al. Plastic and Reconstructive Surgery. 2022;149(6):1326–1336